UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2009

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**0-50626**	**91-1707622**
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

200 Connell Drive, Suite 1500 **Berkeley Heights, New Jersey**	**07922**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(908) 517-7330**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer or Listing.

On December 9, 2009, Cyclacel Pharmaceuticals, Inc. (the "**Company**") received a determination letter from the NASDAQ Listing Qualifications Staff (the "**Staff**") at The NASDAQ Stock Market LLC ("**NASDAQ**") notifying the Company that it does not comply with the $10 million minimum stockholders' equity requirement of the continued listing rules of The NASDAQ Global Market ("**Listing Rules**") set forth in NASDAQ Marketplace Rule 5450(b)(1)(A), and that the Company's securities are subject to delisting, unless the Company appeals the Staff's determination to the NASDAQ Listing Qualifications Panel (the "**Panel**") by no later than December 16, 2009.

The Company intends to request a hearing before the Panel by no later than December 16, 2009, consistent with instructions contained in the determination letter, which will stay the Staff's determination to delist the Company's securities on The NASDAQ Global Market pending the issuance of the Panel's decision. Under NASDAQ's Listing Rules, the Panel may, at its discretion, determine to continue the listing of the Company's securities on The NASDAQ Global Market for a maximum of 180 days from the date of the NASDAQ's determination letter, or through June 7, 2010. There can, however, be no assurance that the Panel will grant the Company's request for continued listing.

On December 15, 2009, the Company issued a press release announcing its receipt of NASDAQ's determination letter. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit is furnished herewith:

99.1 Press release, dated December 15, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYCLACEL PHARMACEUTICALS, INC.

By: /s/ Paul McBarron
Name: Paul McBarron
Title: Executive Vice President — Finance, Chief Financial Officer and Chief Operating Officer

Date: December 15, 2009

Cyclacel Pharmaceuticals, Inc.

P R E S S R E L E A S E

CYCLACEL RECEIVES NASDAQ NOTICE OF NON-COMPLIANCE

Berkeley Heights, NJ, December 15, 2009 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that, on December 9, 2009, the Company was notified by the NASDAQ Staff that the Company does not comply with the minimum $10 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5450(b)(1)(A) (the "Rule") and that the Company's securities are subject to delisting from The Nasdaq Global Market unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel"). Cyclacel intends to timely request a hearing before a Panel, which automatically stays the delisting of the Company's securities pending the issuance of the Panel's decision after a hearing. Under NASDAQ's Listing Rules, the Panel may, at its discretion, determine to continue the Company's listing pursuant to an exception to the Rule for a maximum of 180 days from the date of the Staff's notification or through June 7, 2010. However, there can be no assurances that the Panel will do so.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Risk factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by the interim quarterly reports, filed with the SEC.

Contacts for Cyclacel Pharmaceuticals, Inc.

Investors/Media:
Corey Sohmer, (908) 517-7330
csohmer@cyclacel.com